Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Edelman c/o Abbott Diagnostics

Events

18 Feb 2016 - 20 Feb 2016
25 Feb 2016 - 26 Feb 2016

Molecular Assay Detects Norovirus in Fecal Specimens

By Labmedica International staff writers
Posted on 09 Jan 2014
Print article
Image: The AccuPower Norovirus Real-time RT-PCR assay kit (Photo courtesy of Bioneer Corporation).
Image: The AccuPower Norovirus Real-time RT-PCR assay kit (Photo courtesy of Bioneer Corporation).
A new real-time reverse transcription polymerase chain reaction (RT-PCR) assay has been evaluated in for the detection of human Norovirus in stool specimens.

Noroviruses are a genetically diverse group of single-stranded ribonucleic acid (RNA), nonenveloped viruses in the Caliciviridae family and are classified into five genogroups by phylogenetic analysis of the capsid protein, of which genogroups II (GII), I (GI), and IV (GIV) are responsible for human outbreak.

Scientists at the Hallym University College of Medicine (Seoul, South Korea) analyzed 281 fecal suspensions (10% to 20% fecal specimen diluted with saline) collected and stored at -70 °C between August 2010 and April 2011. These comprised 109 Norovirus-positive and 172 Norovirus-negative stool samples, as determined using a Norovirus enzyme-linked immunosorbent assay (ELISA).

RNA was extracted from fecal suspensions and prepared using the QIAamp Viral RNA Mini Kit (Qiagen; Hilden, Germany) and the Qiagen QIAcube platform. The AccuPower Norovirus Real-time RT-PCR assay (Bioneer Corporation; Daejeon, South Korea) and the RIDAGENE Norovirus V assay (R-Biopharm, Darmstadt, Germany) were compared as Norovirus assays. Norovirus positivity and genotype were confirmed by direct sequencing.

Of the 109 Norovirus-positive samples by ELISA, 91 (83.5%) were positive by both PCR kits, and two (1.8%) were positive only by the AccuPower kit, whereas 16 cases (14.7%) were negative by both PCR kits. Of the 172 Norovirus-negative samples by ELISA, 159 (92.4%) were negative, and five (2.9%) were positive by both PCR kits, one (0.6%) was positive by the RIDAGENE kit, and seven (4.1%) were positive by the AccuPower kit. The lowest mean numbers of genome copies of GI and GII that could be detected by the AccuPower assay were 12.3 and 5.6 RNA copies/reaction, respectively.

The authors concluded that the AccuPower Norovirus Real-time RT-PCR Kit showed good analytical and clinical performance, including excellent analytical sensitivity and reproducibility, without cross-reactivity and they recommend this assay system as an efficient diagnostic tool for Norovirus infection. Noroviruses are responsible for an estimated 218,000 deaths each year among children younger than five years in developing countries and 1.1 million hospitalizations worldwide. The study was published in the January 2014 edition of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Hallym University College of Medicine
Qiagen
Bioneer Corporation 




Print article
Micromedic Technologies

Channels

Immunology

view channel
Image: Micrograph of prostatic adenocarcinoma with perineural invasion, conventional (acinar) type, the most common form of prostate cancer. Prostate biopsy, H&E stain (Photo courtesy of Nephron and Wikimedia).

Reduced PSA Screening May Delay Treatment for Earlier Onset Prostate Cancers

The recommendation against regular prostate specific antigen (PSA) screening for prostate cancer (PCa) has been in place for 2.5 years. The number of prostate needle biopsies (PNB) has been reduced and... Read more

Industry News

view channel
Image: The new CE-marked “illumigene Malaria” DNA amplification assay for detection of Plasmodium spp. DNA in human whole blood samples (Photo courtesy of Meridian Bioscience).

Collaboration Helps Accelerate Launch of New Malaria Test

The recent launch of a new in vitro diagnostic (IVD) assay, CE-marked for detection of Plasmodium spp. DNA in whole blood samples, was accomplished on an accelerated schedule via collaboration with “lean... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.